Candidate selection for prostate cancer focal therapy

Journal of Endourology

Volumn 24, Issue 5, 2010, Pages 835-841

  Taneja, Samir S ^a   Mason, Malcolm ^b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PATIENT; CANCER RISK; CANCER SURGERY; CANCER THERAPY; CLINICAL FEATURE; FOCAL THERAPY; HISTOPATHOLOGY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TRANSPERINEAL SATURATION BIOPSY; TRANSPERINEAL TEMPLATE BIOPSY; TRANSRECTAL BIOPSY; TUMOR BIOPSY;

BIOPSY; HUMANS; MALE; PATIENT SELECTION; PROSTATE; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 77952566896     PISSN: 08927790     EISSN: None     Source Type: Journal    
DOI: 10.1089/end.2010.0006     Document Type: Review

References (69)

1. Ahmed HU, Pendse D, Illing R, et al. Will focal therapy become a standard of care for men with localized prostate cancer? Nat Clin Pract Oncol 2007;4:632-642.
2. Eggener SE, Scardino PT, Carroll PR, et al. Focal therapy for localized prostate cancer: A critical appraisal of rationale and modalities. J Urol 2007;178:2260-2267.
3. Taneja SS, Tareen B. Targeting prostate cancer for focal destruction: Can we find it? Cancer 2008;113:1500-1501.
4. Lindner U, Weersink RA, Haider MA, et al. Image guided photothermal focal therapy for localized prostate cancer: Phase I trial. J Urol 2009;182:1371-1377.
5. Ahmed HU. The index lesion and the origin of prostate cancer. N Engl J Med 2009;361:1704-1706.
6. Ward JF, Nakanishi H, Pisters L, et al. Cancer ablation with regional templates applied to prostatectomy specimens from men who were eligible for focal therapy. BJU Int 2009;104: 490-497.
7. Mouraviev V, Mayes JM, Sun L, et al. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer 2007; 110:906-910.
8. Tareen B, Sankin A, Godoy G, et al. Appropriate candidates for hemiablative focal therapy are infrequently encountered among men selected for radical prostatectomy in contemporary cohort. Urology 2009;73:351-355.
9. Scales CD Jr, Presti JC Jr, Kane CJ, et al. Predicting unilateral prostate cancer based on biopsy features: Implications for focal ablative therapy-results from the SEARCH database. J Urol 2007;178:1249-1252.
10. Wise AM, Stamey TA, McNeal JE, Clayton JL. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 2002;60:264-269.
11. Arora R, Koch MO, Eble JN, et al. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 2004;100:2362-2366.
12. Liu W, Laitinen S, Khan S, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009;15:559-565.
13. Ohori M, Eastham JA, Koh H, et al. Is focal therapy reasonable in patients with early stage prostate cancer (CaP)- an analysis of radical prostatectomy (RP) specimens. J Urol 2006;175(suppl). Abstract 1574.
14. Villers A, McNeal JE, Freiha FS, Stamey TA. Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer 1992;70:2313-2318.
15. Rukstalis DB, Goldknopf JL, Crowley EM, Garcia FU. Prostate cryoablation: A scientific rationale for future modifications. Urology 2002;60(suppl 1):19-25.
16. Gburek BM, Kollmorgen TA, Qian J, et al. Chromosomal anomalies in stage D1 prostate adenocarcinoma primary tumors and lymph node metastases detected by fluorescence in situ hybridization. J Urol 1997;157:223-227.
17. Qian J, Jenkins RB, Bostwick DG. Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization. Mod Pathol 1997;10: 1113-1119. (Pubitemid 27521289)
18. Ahmed HU, Emberton M. Re: Focal therapy for localized prostate cancer: A critical appraisal of rationale and modalities. J Urol 2008;180:780-783.
19. Tareen B, Godoy G, Sankin A, et al. Laterality alone should not drive selection of candidates for hemi-ablative focal therapy. J Urol 2009;181:1082-1090.
20. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-974. (Pubitemid 28445094)
21. Scherr D, Swindle PW, Scardino PT. National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology 2003;61(suppl 1):14-24.
22. Kattan MW, Eastham JA, Wheeler TM, et al. Counseling men with prostate cancer: A nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003;170:1792-1797.
23. Fitzsimons NJ, Presti JC Jr, Kane CJ, et al. Is biopsy Gleason score independently associated with biochemical progression following radical prostatectomy after adjusting for pathological Gleason score? J Urol 2006;176:2453-2458.
24. Greene KL, Elkin EP, Karapetian A, et al. Prostate biopsy tumor extent but not location predicts recurrence after radical prostatectomy: Results from CaPSURE. J Urol 2006;175: 125-129.
25. Rice KR, Furusato B, Chen Y, et al. Clinicopathological behavior of single focus prostate adenocarcinoma. J Urol 2009;182:2689-2694.
26. D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005;294:440-447.
27. Harnden P, Shelley MD, Coles B, et al. Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis. Lancet Oncol 2007;8:411-419.
28. Patel AA, Chen MH, Renshaw AA, D'Amico AV. PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. JAMA 2007;298:1533-1538.
29. Mehra R, Han B, Tomlins SA, et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: Molecular evidence for an independent group of diseases. Cancer Res 2007;67:7991-7995.
30. Gopalan A, Leversha MA, Satagopan JM, et al. TMPRSS2- ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 2009;69:1400-1406.
31. Gregori A, Vieweg J, Dahm P, Paulson DF. Comparison of ultrasound-guided biopsies and prostatectomy specimens: Predictive accuracy of Gleason score and tumor site. Urol Int 2001;66:66-71.
32. Applewhite JC, Matlaga BR, McCullough DL. Results of the 5 region prostate biopsy method: The repeat biopsy population. J Urol 2002;168:500-503.
33. Walz J, Graefen M, Chun FK, et al. High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur Urol 2006;50:498-505.
34. Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 1994;151:1571-1574.
35. Tsivian M, Kimura M, Sun L, et al. Predicting unilateral prostate cancer on routine diagnostic biopsy: Sextant vs extended. BJU Int 2009 Oct 10. Epub ahead of print.
36. Tareen B, Godoy G, Sankin A, et al. Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer? BJU Int 2009;104:195-199.
37. Tareen B, Godoy G, Sankin A, et al. Can biopsy characteristics be used to select men with prostate cancer for focal therapy? Br J Urol 2009;104:195-199.
38. Grossklaus DJ, Coffey CS, Shappell SB, et al. Prediction of tumour volume and pathological stage in radical prostatectomy specimens is not improved by taking more prostate needle-biopsy cores. BJU Int 2001;88:722-726.
39. Borboroglu PG, Comer SW, Riffenburgh RH, Amling CL. Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J Urol 2000;163:158-162.
40. Igel TC, Knight MK, Young PR, et al. Systematic transperineal ultrasound guided template biopsy of the prostate in patients at high risk. J Urol 2001;165:1575-1579.
41. Pinkstaff DM, Igel TC, Petrou SP, et al. Systematic transperineal ultrasound-guided template biopsy of the prostate: Three-year experience. Urology 2005;65:735-739.
42. Buskirk SJ, Pinkstaff DM, Petrou SP, et al. Acute urinary retention after transperineal template-guided prostate biopsy. Int J Radiat Oncol Biol Phys 2004;59:1360-1366.
43. Merrick GS, Taubenslag W, Andreini H, et al. The morbidity of transperineal template-guided prostate mapping biopsy. BJU Int 2008;101:1524-1529.
44. Bott SR, Henderson A, Halls JE, et al. Extensive transperineal template biopsies of prostate: Modified technique and results. Urology 2006;68:1037-1041.
45. Li H, Yan W, Zhou Y, et al. Transperineal ultrasound-guided saturation biopsies using 11-region template of prostate: Report of 303 cases. Urology 2007;70:1157-1161.
46. Moran BJ, Braccioforte MH, Conterato DJ. Re-biopsy of the prostate using a stereotactic transperineal technique. J Urol 2006;176:1376-1381.
47. Satoh T, Matsumoto K, Fujita T, et al. Cancer core distribution in patients diagnosed by extended transperineal prostate biopsy. Urology 2005;66:114-118.
48. Scattoni V, Zlotta A, Montironi R, et al. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: A critical analysis of the literature. Eur Urol 2007;52:1309-1322.
49. Barzell WE, Melamed MR. Appropriate patient selection in the focal treatment of prostate cancer: The role of transperineal 3-dimensional pathologic mapping of the prostate-a 4-year experience. Urology 2007;70(suppl 6): 27-35.
50. Crawford ED, Wilson SS, Torkko KC, et al. Clinical staging of prostate cancer: A computer-simulated study of transperineal prostate biopsy. BJU Int 2005;96:999-1004.
51. Onik G, Miessau M, Bostwick DG. Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol 2009;27:4321-4326.
52. Megwalu II, Ferguson GG, Wei JT, et al. Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer. BJU Int 2008;102:546-550.
53. Fischer GS, DiMaio SP, Iordachita II, Fichtinger G. Robotic assistant for transperineal prostate interventions in 3T closed MRI. Med Image Comput Comput Assist Interv 2007;10: 425-433.
54. Eisenberg ML, Cowan JE, Carroll PR, Shinohara K. The adjunctive use of power Doppler imaging in the preoperative assessment of prostate cancer. BJU Int 2009 Nov 3. Epub ahead of print.
55. Labanaris AP, Engelhard K, Zugor V, et al. Prostate cancer detection using an extended prostate biopsy schema in combination with additional targeted cores from suspicious images in conventional and functional endorectal magnetic resonance imaging of the prostate. Prostate Cancer Prostatic Dis 2010;13:65-70.
56. Kirkham AP, Emberton M, Allen C. How good is MRI at detecting and characterising cancer within the prostate? Eur Urol 2006;50:1163-1175.
57. Larson BT, Collins JM, Huidobro C, et al. Gadoliniumenhanced MRI in the evaluation of minimally invasive treatments of the prostate: Correlation with histopathologic findings. Urology 2003;62:900-904.
58. Langer DL, van der Kwast TH, Evans AJ, et al. Prostate cancer detection with multi-parametric MRI: Logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging 2009;30:327-334.
59. Puech P, Potiron E, Lemaitre L, et al. Dynamic contrastenhanced- magnetic resonance imaging evaluation of intraprostatic prostate cancer: Correlation with radical prostatectomy specimens. Urology 2009;74:1094-1099.
60. Mazaheri Y, Shukla-Dave A, Hricak H, et al. Prostate cancer: Identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging-correlation with pathologic findings. Radiology 2008;246:480-488.
61. Wang P, Guo YM, Liu M, et al. A meta-analysis of the accuracy of prostate cancer studies which use magnetic resonance spectroscopy as a diagnostic tool. Korean J Radiol 2008;9:432-438.
62. Turkbey B, Pinto PA, Choyke PL. Imaging techniques for prostate cancer: implications for focal therapy. Nat Rev Urol 2009;6:191-203.
63. Reske SN, Blumstein NM, Neumaier B, et al. Imaging prostate cancer with 11C-choline PET=CT. J Nucl Med 2006;47:1249-1254.
64. Scher B, Seitz M, Albinger W, et al. Value of 11C-choline PET and PET=CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging 2007;34:45-53.
65. Martorana G, Schiavina R, Corti B, et al. 11C-choline positron emission tomography=computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol 2006;176:954-960.
66. Schmuecking M, Boltze C, Geyer H, et al. Dynamic MRI and CAD vs. choline MRS: where is the detection level for a lesion characterisation in prostate cancer? Int J Radiat Biol 2009;85:814-824.
67. Testa C, Schiavina R, Lodi R, et al. Prostate cancer: Sextant localization with MR imaging, MR spectroscopy, and 11Ccholine PET=CT. Radiology 2007;244:797-806.
68. Villeirs GM, De Meerleer GO, De Visschere PJ, et al. Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: A single-institution experience of 356 patients. Eur J Radiol 2009 Sept 7. Epub ahead of print.
69. Zhang J, Hricak H, Shukla-Dave A, et al. Clinical stage T1c prostate cancer: evaluation with endorectal MR imaging and MR spectroscopic imaging. Radiology 2009;253:425-434.